146 related articles for article (PubMed ID: 21542972)
1. E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma.
Wang H; Satoh M; Chen GP; Li DC; Hamada H; Arai Y
Chin Med J (Engl); 2011 Apr; 124(7):1082-7. PubMed ID: 21542972
[TBL] [Abstract][Full Text] [Related]
2. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
[TBL] [Abstract][Full Text] [Related]
3. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
4. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.
Satoh M; Wang H; Ishidoya S; Abe H; Moriya T; Hamada H; Arai Y
Urology; 2007 Dec; 70(6):1243-8. PubMed ID: 18158069
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y
Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729
[TBL] [Abstract][Full Text] [Related]
7. Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.
Shen YH; Yang F; Wang H; Cai ZJ; Xu YP; Zhao A; Su Y; Zhang G; Zhu SX
PLoS One; 2016; 11(1):e0147173. PubMed ID: 26799485
[TBL] [Abstract][Full Text] [Related]
8. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
9. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
Wei F; Wang H; Chen X; Li C; Huang Q
Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
[TBL] [Abstract][Full Text] [Related]
12. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
14. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
15. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
16. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
17. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virotherapy as a novel strategy for pancreatic cancer.
Sunamura M; Hamada H; Motoi F; Oonuma M; Abe H; Saitoh Y; Hoshida T; Ottomo S; Omura N; Matsuno S
Pancreas; 2004 Apr; 28(3):326-9. PubMed ID: 15084981
[TBL] [Abstract][Full Text] [Related]
19. Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-kappaB activity.
Yamada K; Moriyama H; Yasuda H; Hara K; Maniwa Y; Hamada H; Yokono K; Nagata M
Hum Gene Ther; 2007 May; 18(5):389-400. PubMed ID: 17518613
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
